A significant decrease in earnings
According to recently published financial information, Grífols experienced a 71.5% reduction in its earnings last year, compared to the previous year. This information has been disseminated by the National Securities Market Commission (CNMV).
Factors affecting the results
The pharmaceutical company attributed this decrease to extraordinary items, especially the cost of restructuring, which amounted to 147 million euros. Without these impacts, the profit would have been 206 million euros, according to his statements.
Annual results and future prospects
Despite this significant reduction in earnings, Grífols reported revenues of 6,592 million euros, qualifying the year as a ‘record’. In addition, the company expects to repay the debt with proceeds from the sale of 20% of Shanghai RAAS to Haier.
Debt management and future projections
Grífols emphasized his intention to reduce the debt, with concrete plans to repay it efficiently. In addition, the company hopes to close a ‘strategic’ alliance with Haier during the first half of this year, with the aim of capitalizing on China’s potential in the plasma and diagnostic sectors.